JPMorgan Chase & Co. Upgrades Corteva (NYSE:CTVA) to Overweight

Corteva (NYSE:CTVA) was upgraded by equities research analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm currently has a $19.00 price objective on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 39.07% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. Barclays raised their price target on shares of Corteva from $84.00 to $91.00 and gave the company an “overweight” rating in a research report on Thursday, June 11th. UBS Group lifted their price objective on shares of Corteva from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 16th. Bank of America lifted their price objective on shares of Corteva from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, July 20th. New Street Research set a $17.00 price objective on shares of Corteva in a research report on Monday. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $18.00 price objective on shares of Corteva in a research report on Friday, October 2nd. Sixteen analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $64.00.

Corteva Price Performance

Shares of CTVA stock traded down $0.79 during mid-day trading on Tuesday, hitting $13.66. 35,197,537 shares of the stock were exchanged, compared to its average volume of 25,246,544. The firm has a fifty day moving average of $72.79 and a 200 day moving average of $78.74. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.07. Corteva has a 52-week low of $11.74 and a 52-week high of $90.97. The company has a market cap of $9.12 billion, a PE ratio of 3.81, a price-to-earnings-growth ratio of 1.25 and a beta of 0.57.

Corteva (NYSE:CTVA) last released its earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.24 by $0.06. The business had revenue of $6.38 billion for the quarter, compared to analyst estimates of $6.60 billion. Corteva had a net margin of 5.66% and a return on equity of 10.18%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted $2.20 EPS. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. Research analysts anticipate that Corteva will post 1.69 earnings per share for the current year.

Hedge Funds Weigh In On Corteva

Institutional investors and hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC increased its position in shares of Corteva by 45.3% in the third quarter. Farther Finance Advisors LLC now owns 18,007 shares of the company’s stock worth $1,398,000 after acquiring an additional 5,615 shares in the last quarter. Avidian Wealth Enterprises LLC increased its position in shares of Corteva by 6.3% in the third quarter. Avidian Wealth Enterprises LLC now owns 21,874 shares of the company’s stock worth $1,699,000 after acquiring an additional 1,306 shares in the last quarter. Valeo Financial Advisors LLC increased its position in shares of Corteva by 18.8% in the third quarter. Valeo Financial Advisors LLC now owns 8,273 shares of the company’s stock worth $642,000 after acquiring an additional 1,310 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Corteva in the third quarter worth $81,000. Finally, North Point Portfolio Managers Corp OH acquired a new stake in shares of Corteva in the third quarter worth $1,468,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Key Stories Impacting Corteva

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: KeyBanc upgraded Corteva to Overweight after the Vylor separation and set a $17 price target. The firm expects the streamlined company could achieve “meaningful” earnings growth after 2027, potentially supporting a re-rating of the shares. Corteva upgraded at KeyBanc after spinoff of Vylor
• Positive Sentiment: Options activity was unusually bullish, with investors purchasing 5,408 call options—more than five times typical daily volume. This indicates increased speculative interest in a potential recovery, although options activity is not a guarantee of future performance.
• Positive Sentiment: Commentator Jim Cramer said he would be comfortable building a position in Vylor, the spun-off seed business, suggesting the separation may make the higher-quality growth assets more attractive to investors. However, he remained cautious on Corteva’s crop-protection operations. Jim Cramer Sees One Stock to Own After Corteva’s Breakup
• Neutral Sentiment: KeyCorp maintained an Overweight rating and a $17 target, but its analyst projected only $1.60 in FY2029 EPS. That estimate is below the current-year consensus of $2.77, highlighting uncertainty over the pace and durability of post-spinoff earnings growth.
• Negative Sentiment: Zacks Research downgraded Corteva from Hold to Strong Sell, creating a significant counterweight to the KeyBanc upgrade and likely contributing to investor caution. Corteva Downgraded by Zacks Research

Corteva Company Profile

Corteva, Inc is an agriculture-focused company that develops and supplies seed, crop protection and digital agriculture products. Its offerings are designed to help farmers improve crop productivity, manage pests and diseases, and support more efficient and sustainable farming practices.

The company’s seed portfolio includes corn, soybean, wheat, sunflower, canola, cotton and other crops, marketed through brands such as Pioneer, Brevant seeds and PhytoGen. Corteva also provides herbicides, insecticides, fungicides, biological products and seed treatments under a range of agricultural brands.

Corteva serves farmers, agricultural retailers and other customers in markets around the world.